Dendreon

Dendreon shares jump on news of prostate drug's European launch
Yahoo/Reuters
Mon, 03/3/14 - 10:03 am
Dendreon
prostate cancer
Europe
Provenge
The 10 Most Heavily Shorted Bio-Pharma Stocks
TheStreet.com
Mon, 02/24/14 - 11:15 am
Spectrum Pharmaceuticals
Dendreon
Achillion
Ziopharm
Intrexon
Arena Pharmaceuticals
Idenix
Synta Pharmaceuticals
Sarepta Therapeutics
Myriad Genetics
Galena Biopharma: The Oncologist's Perspective On A Life Saving Therapy
Seeking Alpha
Thu, 02/20/14 - 08:12 am
Galena Biopharma
NeuVax
Dendreon
Provenge
prostate cancer
vaccines
breast cancer
Dendreon: The Time Is Now
Seeking Alpha
Tue, 02/18/14 - 11:33 am
Dendreon
JNJ
Provenge
Medivation
Contract Manufacturing: Often Ignored, But Potentially Profitable
Seeking Alpha
Mon, 02/3/14 - 04:02 pm
contract drug manufacturing
ANI Pharmaceuticals
Dendreon
Teva Pharmaceuticals
NeoStem
What Does Dendreon Corporation's Fourth Quarter Mean For Investors?
Motley Fool
Mon, 02/3/14 - 09:38 am
Dendreon
Provenge
The J.P. Morgan Healthcare Confab Monday Morning News Dump
TheStreet.com
Mon, 01/13/14 - 10:12 am
JPMHC 2014
GSK
Intercept Pharma
Acorda Therapeutics
Cell Therapeutics
Novartis
Sanofi
Alnylam
Idenix
Alexion
Galena Biopharma
Incyte
Clovis Oncology
Dendreon
Merck
Arena Pharmaceuticals
Johnson & Johnson And Medivation: A Prostate Cancer Marketshare
Seeking Alpha
Tue, 01/7/14 - 12:51 pm
JNJ
Medivation
prostatce cancer
Astellas
Dendreon
Sanofi
Zytiga
Xtandi
Provenge
22 Biotech Stock Predictions for 2014
TheStreet.com
Mon, 01/6/14 - 09:47 am
biotech
Vertex Pharmaceuticals
Orexigen
Retrophin
Valeant Pharmaceuticals
Questcor
Biomarin
Merck
NeoStem
Amgen
Gilead Sciences
Vanda
Keryx
Peregrine Pharmaceuticals
CelSci
Regeneron
Cempra
Dendreon
Clovis Oncology
Halozyme
NPS Pharmaceuticals
Argos swings for a $60M IPO in the shadow of Dendreon's struggles
Fierce Biotech
Tue, 12/31/13 - 11:42 am
Argos
IPOs
Dendreon
AGS-003
personalized medicine
renal cell carcinoma
Dendreon: A Cautionary Tale For Biotech Investors
Wall St Cheat Sheet
Mon, 12/30/13 - 11:32 am
Dendreon
Provenge
Inovio CEO Interview: PD1/PDL1 Inhibitors, Immunotherapy And Why Investors Should Be Excited About 2014
Seeking Alpha
Fri, 12/20/13 - 11:49 am
Inovio
Pharma CEOs
PDL-1
immunotherapy
Joseph Kim
Bristol-Myers Squibb
Roche
Dendreon
GSK
ImmunoCellular Therapeutics
Merck
Northwest Biotherapeutics
The Worst Biotech CEO of 2013 Is...
TheStreet.com
Tue, 12/17/13 - 08:48 am
biotech
Vical
Ariad Pharma
Aveo Oncology
Dendreon
Amarin
Dendreon: Where Things Stand Now
Seeking Alpha
Mon, 12/9/13 - 08:42 am
Dendreon
The Provenge Vaccine, A Hedge Fund Manager And The SEC
Pharmalot
Wed, 12/4/13 - 08:47 am
SEC
prostate cancer
Provenge
Dendreon
5 FDA-Approved Drugs That Disappointed Investors in 2013
Motley Fool
Wed, 11/13/13 - 10:33 pm
FDA
Amarin
Vivus
Dendreon
Arena Pharmaceuticals
Provenge
Vascepa
Iclusig
Ariad Pharmaceuticals
Belviq
Qsymia
Dendreon Has Another Disaster Quarter
Seeking Alpha
Wed, 11/13/13 - 10:59 am
Dendreon
earnings
Dendreon to restructure after drop in cancer drug sales
Yahoo/Reuters
Tue, 11/12/13 - 09:17 am
Dendreon
Provenge
restructuring
Will Dendreon Catch Johnson & Johnson or Fall Behind Celldex?
Motley Fool
Mon, 11/11/13 - 10:17 am
Dendreon
JNJ
Celldex
Dendreon (DNDN) Expected to Report More Narrow Loss
Forbes
Fri, 11/8/13 - 10:29 am
earnings
Dendreon

Pages